Figures computed from official regulatory filings — .
Analysttarget 25.71 USD (+878%) · consensus 4.75/5 · 8 buy · 0 hold · 0 sell
Ownershipinsiders 2.3% · institutions 78.39% · short 7.6% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Protara Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
73 buys91 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Shefferman Jesse | Sell | $882.2K | SEC |
| Shefferman Jesse | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shefferman Jesse | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shefferman Jesse | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shefferman Jesse | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shefferman Jesse | Exercise | $412K | SEC |
| Shefferman Jesse | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Huang Jane | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BESHAR LUKE M | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Smith Cynthia | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LEVY RICHARD Strack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GARCEAU ROGER | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SARGEN GREGORY | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Solomon Michael Edward | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Flannelly Barry P | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CONKLING WILLIAM | Other | $26.1K | SEC |
| Zummo Jacqueline | Sell | $6.1K | SEC |
| Zummo Jacqueline | Sell | $118.9K | SEC |
| Fabbio Patrick | Other | $21.8K | SEC |
| Zummo Jacqueline | Other | $24.8K | SEC |
| Shefferman Jesse | Other | $58.2K | SEC |
| Fry Hannah | Other | $9.7K | SEC |
| Fabbio Patrick | Other | $17.2K | SEC |
| Fry Hannah | Other | $11.9K | SEC |
| Shefferman Jesse | Other | $91.4K | SEC |